1800 Williams St., Suite 200 • Denver, CO 80218
Phone 303-388-4876 • Fax 303-336-2193 • Toll Free 1-800-891-7622

URL http://www.rockymountainbmt.com/search/index.php?q=Peripheral Blood Stem Cell (PBSC)&t=

Search

Your search returned 8 results.

Pegfilgrastim mobilizes peripheral blood stem cells in poor mobilizer multiple myeloma
06-07-2006 Pegfilgrastim mobilizes peripheral blood stem cells in a poor mobilizer multiple myeloma patient. "Studies performed on mice and healthy human volunteers have shown that a single dose of pegfilgrastim (Peg-GCSF) is effective in stimulating peripheral blood stem cells (PBSC) mobilization.
http://www.rockymountainbmt.com/news/Pegfilgrastim-mobilizes-peripheral-blood-stem-cells-in-poor-mobilizer-multiple-myeloma-959.html - 9k - 100%

Researchers' work from University of Heidelberg, Department of Internal Medicine focuses on myeloma
03-26-2007 Scientists discuss in "Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation" new findings in myeloma. According to recent research from Heidelberg, Germany, "We analyzed the hematopoietic reconstitution and outcome of 508 patients with multiple myeloma (MM) with respect to the number of CD34+ cells reinfused at our center.
http://www.rockymountainbmt.com/news/Researchers-work-from-University-of-Heidelberg-Department-of-Internal-Medicine-focuses-on-myeloma-10782.html - 9k - 81.1%

Myelodysplastic Syndrome (MDS)
What is Myelodysplastic Syndrome? Myelodysplastic syndrome (MDS) is a disorder in which the bone marrow does not make blood cells appropriately and in great enough numbers. This results in low numbers of red blood cells, white blood cells, platelets or all three.
http://www.rockymountainbmt.com/diseases/Myelodysplastic-Syndrome-MDS-29.html - 19k - 81.1%

Refractory cytomegalovirus infection successfully treated after stem cell transplant
08-17-2006 Foscarnet plus leflunomide successfully treats refractory cytomegalovirus infection following stem cell transplantation. According to a recent report from Germany, "Treatment of cytomegalovirus (CMV) disease after allogeneic hematopoietic stem cell transplantation (HSCT) is limited by toxicities of current antiviral drugs and the occurrence of drug resistant strains.
http://www.rockymountainbmt.com/news/Refractory-cytomegalovirus-infection-successfully-treated-after-stem-cell-transplant-2649.html - 8k - 80.9%

Researchers' work from University of Heidelberg, Department of Internal Medicine focuses on myeloma
03-22-2007 Scientists discuss in "Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation" new findings in myeloma. According to recent research from Heidelberg, Germany, "We analyzed the hematopoietic reconstitution and outcome of 508 patients with multiple myeloma (MM) with respect to the number of CD34+ cells reinfused at our center.
http://www.rockymountainbmt.com/news/Researchers-work-from-University-of-Heidelberg-Department-of-Internal-Medicine-focuses-on-myeloma-10985.html - 8k - 78.4%

Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial
Principal Investigator: Michael B. Maris, MD Protocol Number: RMBMT-152 Major Objectives To determine which dose of Campath allows related and unrelated HLA class-II mismatched HCT with an incidence of grade III-IV acute GVHD Minor Objectives Incidence of graft rejection Number of days of steroids 1mg/kg required before day 100 in each patient.
http://www.rockymountainbmt.com/clinical_trials/Campath-Alemtuzumab-Dose-Escalation-Low-Dose-TBI-and-Fludarabine-Followed-by-HLA-Class-II-Mismatched-Donor-Stem-Cell-Transplantation-For-Patients-With-Hematologic-Malignancies---A-Multicenter-Trial-35.html - 16k - 66.4%

Bone Marrow Transplant (BMT), Colorado BMT, Stem Cell Transplant Colorado, Cord Blood Transplant, Denver, Colorado, Kansas, Nebraska, New Mexico, South Dakota, Utah, Wyoming, Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Amyloidosis, Apl

http://www.rockymountainbmt.com/index.html - 9k - 64.3%

1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia
Principal Investigator: Peter A. McSweeney, MD Protocol Number: RMBMT 159 Major Objectives Determine whether the conditioning intensity affects outcomes after HCT in patients with MDS or AML who have <5% marrow myeloblasts at the time of HCT. Patient Selection Inclusion Criteria: MDS or tAML (transformed from MDS) De novo AML beyond first remission Intermediate or high risk de novo AML in first complete response-(unrelated donor recipients only) Chemotherapy required prior to HCT for all patients Interval between start of a cycle of chemotherapy and infusion of donor stem cells must be at least 30 days.
http://www.rockymountainbmt.com/clinical_trials/1992---A-Multi-center-Phase-III-Study-Comparing-Myeloablative-to-Nonmyeloablative-Transplant-Conditioning-in-Patients-with-Myelodysplastic-Syndrome-or-Acute-Myelogenous-Leukemia-52.html - 11k - 51.2%